Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy

Author(s): Predrag Sikiric*, Domagoj Drmic, Marko Sever, Robert Klicek, Alenka B. Blagaic, Ante Tvrdeic, Tamara Kralj, Katarina K. Kovac, Jaksa Vukojevic, Marko Siroglavic, Slaven Gojkovic, Ivan Krezic, Katarina H. Pavlov, Domagoj Rasic, Ivan Mirkovic, Antonio Kokot, Anita Skrtic, Sven Seiwerth

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 25 , 2020

Become EABM
Become Reviewer

Abstract:

This review is focused on the healing of fistulas and stable gastric pentadecapeptide BPC 157. Assuming that the healing of the various wounds is essential also for the gastrointestinal fistulas healing, the healing effect on fistulas in rats, consistently noted with the stable gastric pentadecapeptide BPC 157, may raise several interesting possibilities. BPC 157 is originally an anti-ulcer agent, native to and stable in human gastric juice (for more than 24 h). Likely, it is a novel mediator of Robert’s cytoprotection maintaining gastrointestinal mucosal integrity. Namely, it is effective in the whole gastrointestinal tract, and heals various wounds (i.e., skin, muscle, tendon, ligament, bone; ulcers in the entire gastrointestinal tract; corneal ulcer); LD1 is not achieved. It is used in ulcerative colitis clinical trials, and now in multiple sclerosis, and addressed in several reviews. Therefore, it is not surprising that BPC 157 has documented consistent healing of the various gastrointestinal fistulas, external (esophagocutaneous, gastrocutaneous, duodenocutaneous, colocutaneous) and internal (colovesical, rectovaginal). Taking fistulas as a pathological connection, this rescue is verified with the beneficial effects in rats with the various gastrointestinal anastomoses, esophagogastric, jejunoileal, colo-colonic, ileoileal, esophagojejunal, esophagoduodenal, and gastrojejunal. This beneficial effect occurs equally when the gastrointestinal anastomoses are impaired with the application of NSAIDs, cysteamine, large bowel resection, as well as concomitant esophageal, gastric, and duodenal lesions and/or ulcerative colitis presentation, short bowel syndrome progression, liver and brain disturbances presentation. Particular aspects of the BPC 157 healing of the fistulas are especially emphasized.

Keywords: Stable gastric pentadecapeptide BPC 157, fistulas healing, therapy, esophagoduodenal, colovesical, rectovaginal.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 25
Year: 2020
Page: [2991 - 3000]
Pages: 10
DOI: 10.2174/1381612826666200424180139
Price: $65

Article Metrics

PDF: 4